Hormone Replacement Therapy (HRT)
- 15 Downloads
Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, combination, duration of use, route of administration, and timing of initiation. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT.
For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture.
For women who initiate HT more than 10 years from menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, and venous thromboembolism. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. New and emerging menopausal therapies have the potential to relieve menopausal symptoms and to create a target treatment.
KeywordsBreast cancer Cardiovascular disease Estrogen Hormone replacement therapy Menopause Osteoporosis Vaginal atrophy Vasomotor symptoms
- American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. 2019.Google Scholar
- Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, Santoro N, Simoncini T. Menopause. PRIMER. 2015;I:4.Google Scholar
- Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84:961–7.CrossRefGoogle Scholar
- Huber J, Birkhäuser M, Metka M, Druckmann R, Rohr U, Winkler T. Europäische Gynäkologen analysieren die WHIStudie – Hormonstudie amerikanischer Kardiologen. J Menopause. 2002;9:7–13.Google Scholar
- Huber J, Birkhäuser M, Metka M, Druckmann R, Rohr U, Winkler T, Schindler AE, Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Services Task Force Recommendations. Ann Int Med. 2012;157:104–10.CrossRefGoogle Scholar
- Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA, Hereditary breast cancer clinical study group. Hormone replacement therapy after oophorectomy andand breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059–65.CrossRefGoogle Scholar
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004a;4:CD002978.Google Scholar
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004b;4:CD002978.Google Scholar
- Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Pergnola G, … Benedetti Panici P. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol. 2018;132:111–115.CrossRefGoogle Scholar
- Olie V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18:488493.Google Scholar
- Osteoporosis. In: National institutes of health consensus development conference statement, April 2–4, 1984. Department of Health & Human ServicesGoogle Scholar
- Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) trials. J Womens Health (Larchmt). 2014;23(1):18–28.CrossRefGoogle Scholar
- Pluchino N, Genazzani AR. DHEA replacement for postmenopausal women: have we been looking in the right direction? Climacteric. 2015;18:1–3.Google Scholar
- Practice bulletin no. 141 management of menopausal symptoms. Obstet Gynecol 2014; 123(1):202–216.Google Scholar
- Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2014;17:1–14.Google Scholar
- Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95:4985–92.CrossRefGoogle Scholar
- Somboonporn W, Bell RJ, Davis SR. Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev. 2005;19;(4):CD004509.Google Scholar